Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor β subtype selective agonist KB-141

Journal of Steroid Biochemistry and Molecular Biology

Volumn 111, Issue 3-5, 2008, Pages 262-267

  Bryzgalova, Galina ^a   Effendic, Suad ^a   Khan, Akhtar ^a   Rehnmark, Stefan ^b   Barbounis, Peter ^c   Boulet, Jamie ^c   Dong, Gao ^c   Singh, Rajni ^c   Shapses, Sue ^d   Malm, Johan ^b   Webb, Paul ^e   Baxter, John D ^e   Grover, Gary J ^c,f  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Karo Bio   (Sweden)

^c Eurofins Medinet Inc   (Germany)

^d RUTGERS UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Cholesterol; KB 141; Obesity; Thyroid hormones

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTIOBESITY AGENT; CHOLESTEROL; FATTY ACID; HORMONE RECEPTOR STIMULATING AGENT; KB 141; THYROID HORMONE RECEPTOR BETA; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE TOLERANCE; HEART RATE; HYPERLIPIDEMIA; INSULIN SENSITIVITY; LIPID LIVER LEVEL; METABOLIC SYNDROME X; NONHUMAN; OBESITY; RAT; TACHYCARDIA; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; ZUCKER DIABETIC FATTY RAT;

ANIMALS; ANTI-OBESITY AGENTS; ANTILIPEMIC AGENTS; BODY WEIGHT; DIABETES MELLITUS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPOGLYCEMIC AGENTS; MICE; MICE, OBESE; MOLECULAR STRUCTURE; OBESITY; PHENYL ETHERS; PHENYLACETATES; RATS; RATS, ZUCKER; THYROID HORMONE RECEPTORS BETA;

ANIMALIA; MUS; RATTUS;

EID: 49649120105     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2008.06.010     Document Type: Article

References (28)

1. Simpkins S. Dintrophenol and desiccated thyroid in the treatment of obesity. JAMA 108 (1937) 2110-2119
2. Malm J. Thyroid hormone ligands and metabolic diseases. Curr. Pharmaceut. Des. 10 (2004) 3525-3532
3. Lazar M.A. Thyroid hormone receptors: multiple forms, multiple possibilities. Endocrol. Rev. 14 (1993) 348-399
4. Weigle D.S. Pharmacological therapy of obesity: past, present, and future. J. Clin. Endocrinol. Metab. 45 (2003) 2462-2469
5. Clapham J.C. Treating obesity: pharmacology of energy expenditure. Curr. Drug Targets 5 (2004) 309-323
6. Bravermam L., and Utiger R.D. Introduction to hypothyroidism. In: Braverman L., and Utiger R.D. (Eds). The Thyroid: A Fundamental and Clinical Text (1996), Lippincot-Raven, New York 736-765
7. Yen P.M. Physiological and molecular basis of thyroid hormone action. Physiol. Rev. 81 (2001) 1097-1142
8. Grover G., Mellstrom K., Ye L., Malm J., Li-Y L., Bladh L., Sleph P.G., Smith M.A., George R., Vennstrom B., Mookhtiar K., Horvath R., Speelman J.D., Egan, and Baxter J.D. Selective thyroid hormone receptorβ activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liabililty. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 10067-10072
9. Freake J.C., Schwartz H.L., and Oppenheimer J.H. The regulation of lipogenesis by thyroid hormone and its contribution to thermogenesis. Endocrinology 125 (1989) 2674-2868
10. Ness G.C., Lopez D., Chambers C.M., Newsome W.P., Cornelius P., Long C.A., and Harwood Jr. H.J. Effects of l-triiodothyronine and the thyromimetic L-94901 on serum lipoprotein levels and hepatic LDL-receptor, 3-hydroxy-3-methyglutaryl coenzyme A reductase, and Apo A-I gene expression. Biochem. Pharm. 56 (1998) 121-129
11. Grover G.J., and Malm J. Thyroid hormone modulators: a strategy for treating metabolic syndrome. Drug Discov. Today: Ther. Strategies 2 (2005) 137-142
12. Klein I., and Ojamaa K. Thyroid hormone and the cardiovascular system. N. Engl. J. Med. 344 (2001) 501-509
13. Malm J. Thyroid hormone ligands and metabolic diseases. Curr. Pharm. Des. 10 (2004) 3525-3532
14. Erion M.D., Cable E.E., Ito B.R., Jiang H., Finn J.D., Zhang B.-H., Hou J., Boyer S.H., van Peter P.D., and Linemeyer D.L. Targeting throid hormone receptor-b agonists to the liver lowers cholesterol and triglycerides and improves the therapeutic index. Proc. Natl. Acad. Sci. U.S.A. 58 (2007) 15490-15495
15. Schwartz H.L., Strait K.A., Ling N.C., and Oppenheimer J.H. Quantitation of rat tissue thyroid hormone binding receptor isoforms by immunoprecipitation of nuclear triiodothyronine binding capacity. J. Biol. Chem. 267 (1992) 11794-11799
16. Wikström L., Johansson C., Salto C., Barlow C., Campos A., Barros A., Baas F., Forrest D., Thoren P., and Vennstrom B. Abnormal heart rate and body temperature in mice lacking thyroid hormone receptor alpha-1. EMBO J. 17 (1998) 455-461
17. Johansson C., Vennström B., and Thoren P. Evidence that decreased heart rate in thyroid hormone receptor-β1-deficient mice is an intrinsic defect. Am. J. Physiol. 275 (1998) R640-R646
18. Trost S., Swanson E., Gloss B., Wang-Iverson D.B., Zhang H., Volodarsky T., Grover G.J., Baxter J.D., Chiellini G., Scanlan T.S., and Dillmann W.H. The thyroid hormone receptor-beta-selective agonist GC-1 differentially affects plasma lipids and cardiac activity. Endocrinology 141 (2000) 3057-3064
19. Grover G.J., Egan D., Sleph P.G., Beehler B.C., Chiellini G., Ngoc-Ha N., Baxter J.D., and Scanlan T.S. Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3′-triiodo-thyronine. Endocrinology 145 (2004) 1656-1661
20. Villicev C.M., Freitas F.R.S., Aoki M.S., Taffarel C., Scanlan T.S., Moriscot A.S., Ribeiro M.O., Bianco A.C., and Goiuveia C.H.A. Thyroid hormone receptor β-specific agonist GC-1 increases energy expenditure and prevents fat-mass accumulation in rats. J. Endocrinol. 193 (2007) 21-29
21. Dimitriadis G., Baker B., and Marsh H. Effect of thyroid hormone excess on action, secretion, and metabolism of insulin in humans. Am. J. Physiol. 248 (1985) E593-E598
22. Acotto C.G., Niepomniszcze H., and Mautalen C.A. Estimating body fat and lean tissue distribution in hyperthyroidism by dual-energy X-ray absorptiometry. J. Clin. Densitom. 5 (2002) 305-311
23. Lonn L., Stenlof K., Ottosson M., Lindroos A.K., Nystrom E., and Sjostrom L. Body weight and body composition changes after treatment of hyperthyroidism. J. Clin. Endocrinol. Metab. 83 (1998) 4269-4273
24. Beylot M., Martin C., Laville M., Riou J.P., Cohen R., and Mornex R. Lipolytic and ketogenic fluxes in human hyperthyroidism. J. Clin. Endocrinol. Metab. 73 (1991) 42-49
25. Grundy S.M. Metabolic complications of obesity. Endocr. J. 13 (2000) 155-165
26. Weinstein S.P., Watts J., and Haber R.S. Thyroid hormone increases muscle/fat glucose transporter gene expression in rat skeletal muscle. Endocrinology 129 (1991) 455-462
27. Weinstein S.P., Watts J., Graves P.N., and Haber R.S. Stimulation of glucose transport by thyroid hormone in ARL 15 cells: increased abundance of glucose transporter protein and messenger ribonucleic acid. Endocrinology 126 (1990) 1421-1429
28. Marecek R.L., and Feldman J.M. Effect of hyperthyroidism on insulin and glucose dynamics in rabbits. Endocrinology 92 (1973) 1604-1610